/CATX

Perspective Therapeutics Inc

CATX

$2.81USD↑+1.44%+0.04 today

MARKET CAP

320.8M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$2

$6

AI Summary

Stalk

Sell NowHigh

CATX remains in a high-confidence Stage 4 decline, trading below all major moving averages with no active patterns to support a rally. Medium-term bearish structure is intact under a sequence of lower highs and lower lows, and short-term conditions show a lack of upside follow-through into declining EMAs. Execution should focus on selling into any relief rallies around the 9/21 EMA zone. A decisive close and hold above those EMAs would invalidate the bearish bias.

↑Completed PSV359 Phase1/2a dosing, enabling next pivotal trials.
↑Analyst consensus Buy with $11.50 target implies 248.5% upside.
↓Q2 net loss $26.8M strains cash runway amid revenue shortfall.

Full analysis →

Buying

9

institutions

Selling

1

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	9.49 M	32.38 M	+4.15 M	+45.2%	0.00%
MM Millennium Management LLC Q2 2026	BUY	4.91 M	16.75 M	+865.22 K	-0.7%	0.01%
CA Citadel Advisors LLC Q2 2026	BUY	3.81 M	12.98 M	+165.53 K	-14.5%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	BUY	3.32 M	11.32 M	+325.76 K	-9.3%	0.01%
AC Adar1 Capital Management, LLC Q2 2026	BUY	1.21 M	4.13 M	+460.78 K	+32.1%	0.19%
RT Renaissance Technologies LLC Q2 2026	BUYNEW	59.13 K	201.64 K	+59.13 K	+0.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	47.14 K	167.34 K	+17.90 K	+49.4%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	28.00 K	95.47 K	+1.28 K	-14.3%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUYNEW	13.73 K	46.81 K	+13.73 K	+0.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	0.00	0.00	+-3.00 K	-100.0%	0.00%